About Concert Pharmaceuticals (NASDAQ:CNCE)
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, which has completed the Phase 1 clinical trials for the treatment of patients with narcolepsy; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata. The company is also developing CTP-692, a selective deuterium-modified analog of the endogenous amino acid, D-serine, which is in preclinical studies for use in the treatment of patients with schizophrenia. It has strategic collaborations with Celgene Pharmaceuticals, Inc.; Celgene International Sarl; Celgene Corporation; Avanir Pharmaceuticals, Inc.; and Jazz Pharmaceuticals, Inc. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E Ratio4.62
Forward P/E Ratio-8.12
Sales & Book Value
Annual Sales$143.89 million
Price / Sales3.08
Cash Flow$4.2212 per share
Price / Cash4.52
Book Value$8.63 per share
Price / Book2.21
EPS (Most Recent Fiscal Year)$4.08
Net Income$95.63 million
Return on Equity-36.25%
Return on Assets-31.01%
Concert Pharmaceuticals (NASDAQ:CNCE) Frequently Asked Questions
What is Concert Pharmaceuticals' stock symbol?
Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."
How were Concert Pharmaceuticals' earnings last quarter?
Concert Pharmaceuticals (NASDAQ:CNCE) issued its quarterly earnings data on Thursday, March, 1st. The biotechnology company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by $0.08. The biotechnology company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $8.11 million. Concert Pharmaceuticals had a net margin of 66.47% and a negative return on equity of 36.25%. View Concert Pharmaceuticals' Earnings History.
What price target have analysts set for CNCE?
5 analysts have issued 12 month target prices for Concert Pharmaceuticals' shares. Their predictions range from $25.00 to $34.00. On average, they expect Concert Pharmaceuticals' share price to reach $27.60 in the next year. View Analyst Ratings for Concert Pharmaceuticals.
What are Wall Street analysts saying about Concert Pharmaceuticals stock?
Here are some recent quotes from research analysts about Concert Pharmaceuticals stock:
- 1. Mizuho analysts commented, "We don’t see a read-through from today’s news to the ultimate outcome of the IPR challenge. Based on how Concert has defended its patents historically and the impressive track record on IP protection front, we think it is likely they can win this challenge. PTAB Proceedings. In April 2017, Incyte filed an Inter Partes Review Petition (IPR) against Concert seeking to invalidate Concert’s U.S. Patent No. 9,249,149. Following this, in October 2017, the PTAB denied Incyte’s petition to institute the IPR. Today, the PTAB is granting Incyte’s motion for reconsideration. Oral arguments between the parties will be made in December followed by a PTAB decision, expected in April 2019. PLEASE REFER TO PAGE 3 OF THIS REPORT FOR IMPORTANT DISCLOSURE AND ANALYST CERTIFICATION INFORMATION. Mizuho Securities USA LLC does and seeks to do business with companies covered in its research reports." (4/10/2018)
- 2. According to Zacks Investment Research, "Concert Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on applying its DCE Platform (R) to create novel small molecule drugs. The Company manufactures drugs in various therapeutic areas such as hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, and schizophrenia, multiple tumors, and hyperparathyroidism. Concert Pharmaceuticals Inc. is based in United States. " (3/8/2018)
Who are some of Concert Pharmaceuticals' key competitors?
Some companies that are related to Concert Pharmaceuticals include Phibro Animal Health (PAHC), Akcea Therapeutics (AKCA), OPKO Health (OPK), Madrigal Pharmaceuticals (MDGL), Enanta Pharmaceuticals (ENTA), Innoviva (INVA), Xencor (XNCR), Prestige Brands (PBH), Radius Health (RDUS), Impax Laboratories (IPXL), Pacira Pharmaceuticals (PCRX), Zogenix (ZGNX), Prothena (PRTA), ImmunoGen (IMGN) and Immuron (IMRN).
Who are Concert Pharmaceuticals' key executives?
Concert Pharmaceuticals' management team includes the folowing people:
- Mr. Richard H. Aldrich, Co-Founder & Chairman (Age 64)
- Dr. Roger D. Tung, Co-Founder, CEO, Pres & Director (Age 58)
- Ms. Nancy Stuart, Chief Operating Officer (Age 60)
- Dr. James V. Cassella, Chief Devel. Officer (Age 63)
- Mr. Marc A. Becker, Chief Financial Officer (Age 46)
Has Concert Pharmaceuticals been receiving favorable news coverage?
News coverage about CNCE stock has been trending somewhat positive on Tuesday, Accern Sentiment reports. Accern identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Concert Pharmaceuticals earned a coverage optimism score of 0.24 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 45.04 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.
How do I buy shares of Concert Pharmaceuticals?
Shares of CNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Concert Pharmaceuticals' stock price today?
One share of CNCE stock can currently be purchased for approximately $19.08.
How big of a company is Concert Pharmaceuticals?
Concert Pharmaceuticals has a market capitalization of $445.15 million and generates $143.89 million in revenue each year. The biotechnology company earns $95.63 million in net income (profit) each year or $4.08 on an earnings per share basis. Concert Pharmaceuticals employs 64 workers across the globe.
How can I contact Concert Pharmaceuticals?
Concert Pharmaceuticals' mailing address is 99 HAYDEN AVENUE SUITE 500, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-860-0045 or via email at [email protected]
MarketBeat Community Rating for Concert Pharmaceuticals (CNCE)MarketBeat's community ratings are surveys of what our community members think about Concert Pharmaceuticals and other stocks. Vote "Outperform" if you believe CNCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
Concert Pharmaceuticals (NASDAQ:CNCE) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Concert Pharmaceuticals (NASDAQ CNCE) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 10.10%
Institutional Ownership Percentage: 72.65%
Concert Pharmaceuticals (NASDAQ CNCE) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|4/17/2018||James V Cassella||Insider||Sell||10,582||$20.18||$213,544.76||30,000|| |
|2/1/2018||Richard Aldrich||Director||Sell||11,946||$20.89||$249,551.94||286,975|| |
|1/29/2018||Richard Aldrich||Director||Sell||18,054||$20.63||$372,454.02||286,975|| |
|1/26/2018||Richard Aldrich||Director||Sell||5,000||$20.46||$102,300.00||286,975|| |
|1/24/2018||Richard Aldrich||Director||Sell||30,000||$19.68||$590,400.00||286,975|| |
|1/22/2018||Richard Aldrich||Director||Sell||10,000||$19.55||$195,500.00||286,975|| |
|1/19/2018||Richard Aldrich||Director||Sell||30,000||$19.35||$580,500.00||286,975|| |
|1/16/2018||Richard Aldrich||Director||Sell||31,236||$19.14||$597,857.04||286,975|| |
|12/19/2017||Value Fund L P Biotechnology||Insider||Sell||1,282,856||$26.65||$34,188,112.40|| |
|12/4/2017||Ronald W Barrett||Director||Sell||14,156||$24.70||$349,653.20||3,539|| |
|10/19/2017||Value Fund L P Biotechnology||Insider||Buy||331,916||$15.84||$5,257,549.44|| |
|9/14/2017||Ryan Lynch||Insider||Sell||3,500||$14.51||$50,785.00||9,500|| |
|5/12/2016||Thomas G Auchincloss||Director||Buy||2,000||$10.11||$20,220.00||2,000|| |
|5/11/2016||Roger D Tung||CEO||Buy||19,610||$10.55||$206,885.50||538,965|| |
|12/16/2015||Wilfred E Jaeger||Director||Sell||10,360||$19.57||$202,745.20|| |
|12/15/2015||Wilfred E Jaeger||Director||Sell||54,572||$20.10||$1,096,897.20|| |
|12/14/2015||Pauline Mcgowan||VP||Sell||498||$20.07||$9,994.86|| |
|12/14/2015||Wilfred E Jaeger||Director||Sell||3,922||$20.09||$78,792.98|| |
|11/9/2015||Ronald W. Barrett||Director||Sell||17,699||$22.27||$394,156.73|| |
|11/2/2015||Nancy Stuart||COO||Sell||23,216||$24.29||$563,916.64||25,004|| |
|9/18/2015||Robert Silverman||VP||Sell||10,000||$20.00||$200,000.00||10,000|| |
|9/10/2015||Wilfred E Jaeger||Director||Sell||120,000||$18.22||$2,186,400.00|| |
|8/18/2015||Wilfred E Jaeger||Director||Sell||760,000||$15.81||$12,015,600.00|| |
|8/13/2015||Wilfred E Jaeger||Director||Sell||92,215||$16.75||$1,544,601.25|| |
|8/12/2015||Wilfred E Jaeger||Director||Sell||97,785||$17.49||$1,710,259.65|| |
|6/8/2015||Robert Silverman||VP||Sell||5,000||$16.35||$81,750.00|| |
|3/11/2015||Nancy Stuart||COO||Sell||46,430||$15.00||$696,450.00|| |
|3/11/2015||Pauline Mcgowan||VP||Sell||5,973||$16.00||$95,568.00|| |
|3/10/2015||Pauline Mcgowan||VP||Sell||22,122||$13.90||$307,495.80|| |
|11/18/2014||Three Arch Management Iv, L.L.||Director||Sell||250,000||$12.29||$3,072,500.00|| |
|2/20/2014||Skyline Venture Partners Quali||Major Shareholder||Buy||150,000||$14.00||$2,100,000.00|| |
|2/19/2014||Life Science Ventures Vi G Tvm||Director||Buy||89,000||$14.00||$1,246,000.00|| |
|2/19/2014||Plc Glaxosmithkline||Major Shareholder||Buy||35,000||$14.00||$490,000.00|| |
Concert Pharmaceuticals (NASDAQ CNCE) News Headlines
Concert Pharmaceuticals (NASDAQ:CNCE) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Concert Pharmaceuticals (NASDAQ:CNCE) Income Statement, Balance Sheet and Cash Flow Statement
Concert Pharmaceuticals (NASDAQ CNCE) Stock Chart for Tuesday, April, 24, 2018